Use of praziquantel as an adjuvant enhances protection and Tc-17 responses to killed H5N1 virus vaccine in mice

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Zou, Qiang ^a,b   Hu, Yanxin ^b   Xue, Jia ^b   Fan, Xiaoxu ^b   Jin, Yi ^b   Shi, Xianghua ^b   Meng, Di ^b   Wang, Xianzheng ^a   Feng, Congcong ^b   Xie, Xiaoping ^b   Zhang, Yizhi ^b   Kang, Youmin ^b   Liang, Xiaoxuan ^b   Wu, Bing ^b   Wang, Ming ^b   Wang, Bin ^a,b  

^a FUDAN UNIVERSITY   (China)

^b CHINA AGRICULTURAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; CYTOKINE; GAMMA INTERFERON; INFLUENZA VACCINE; INTERLEUKIN 17; PRAZIQUANTEL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; C57BL 6 MOUSE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; FEMALE; INFLUENZA A (H5N1); INOCULATION; KNOCKOUT MOUSE; MOUSE; NONHUMAN; SINGLE DRUG DOSE; SURVIVAL RATE; VIRUS LOAD; WILD TYPE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; ORTHOMYXOVIRIDAE INFECTIONS; PRAZIQUANTEL; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, INACTIVATED;

EID: 84859949727     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0034865     Document Type: Article

References (50)

1. Doherty PC, Turner SJ, Webby RG, Thomas PG, (2006) Influenza and the challenge for immunology. Nat Immunol 7: 449-455.
2. Russell CJ, Webster RG, (2005) The genesis of a pandemic influenza virus. Cell 123: 368-371.
3. Yamada S, Suzuki Y, Suzuki T, Le MQ, Nidom CA, et al. (2006) Haemagglutinin mutations responsible for the binding of H5N1 influenza A viruses to human-type receptors. Nature 444: 378-382.
4. Palese P, Garcia-Sastre A, (2002) Influenza vaccines: present and future. J Clin Invest 110: 9-13.
5. Schmitz JE, Kuroda MJ, Santra S, Simon MA, Lifton MA, et al. (2003) Effect of humoral immune responses on controlling viremia during primary infection of rhesus monkeys with simian immunodeficiency virus. J Virol 77: 2165-2173.
6. Lau YF, Tang LH, McCall AW, Ooi EE, Subbarao K, (2010) An adjuvant for the induction of potent, protective humoral responses to an H5N1 influenza virus vaccine with antigen-sparing effect in mice. J Virol 84: 8639-8649.
7. Bender BS, Croghan T, Zhang L, Small PA Jr, (1992) Transgenic mice lacking class I major histocompatibility complex-restricted T cells have delayed viral clearance and increased mortality after influenza virus challenge. J Exp Med 175: 1143-1145.
8. Eichelberger M, Allan W, Zijlstra M, Jaenisch R, Doherty PC, (1991) Clearance of influenza virus respiratory infection in mice lacking class I major histocompatibility complex-restricted CD8+ T cells. J Exp Med 174: 875-880.
9. Huang MH, Lin SC, Hsiao CH, Chao HJ, Yang HR, et al. (2010) Emulsified nanoparticles containing inactivated influenza virus and CpG oligodeoxynucleotides critically influences the host immune responses in mice. PLoS One 5: e12279.
10. Schubert C, (2009) Boosting our best shot. Nat Med 15: 984-988.
11. El Sahly H, (2010) MF59 as a vaccine adjuvant: a review of safety and immunogenicity. Expert Rev Vaccines 9: 1135-1141.
12. Kistner O, Howard MK, Spruth M, Wodal W, Bruhl P, et al. (2007) Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine 25: 6028-6036.
13. Ninomiya A, Imai M, Tashiro M, Odagiri T, (2007) Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model. Vaccine 25: 3554-3560.
14. Exley C, (2004) Aluminium-containing DTP vaccines. Lancet Infect Dis 4: 324; discussion 325.
15. Nicholson KG, Colegate AE, Podda A, Stephenson I, Wood J, et al. (2001) Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 357: 1937-1943.
16. Wack A, Baudner BC, Hilbert AK, Manini I, Nuti S, et al. (2008) Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine 26: 552-561.
17. Cioli D, Pica-Mattoccia L, (2003) Praziquantel. Parasitol Res 90 (Supp 1): S3-9.
18. Zou Q, Zhong Y, Su H, Kang Y, Jin J, et al. (2010) Enhancement of humoral and cellular responses to HBsAg DNA vaccination by immunization with praziquantel through inhibition TGF-beta/Smad2,3 signaling. Vaccine 28: 2032-2038.
19. Zou Q, Yao X, Feng J, Yin Z, Flavell R, et al. (2011) Praziquantel facilitates IFN-gamma-producing CD8+ T cells (Tc1) and IL-17-producing CD8+ T cells (Tc17) responses to DNA vaccination in mice. PLoS One 6: e25525.
20. Ortega C, Fernandez AS, Carrillo JM, Romero P, Molina IJ, et al. (2009) IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines. J Leukoc Biol 86: 435-443.
21. Park KD, Marti L, Kurtzberg J, Szabolcs P, (2006) In vitro priming and expansion of cytomegalovirus-specific Th1 and Tc1 T cells from naive cord blood lymphocytes. Blood 108: 1770-1773.
22. Yeh N, Glosson NL, Wang N, Guindon L, McKinley C, et al. (2010) Tc17 cells are capable of mediating immunity to vaccinia virus by acquisition of a cytotoxic phenotype. J Immunol 185: 2089-2098.
23. McMichael AJ, Gotch FM, Noble GR, Beare PA, (1983) Cytotoxic T-cell immunity to influenza. N Engl J Med 309: 13-17.
24. Boon AC, de Mutsert G, Graus YM, Fouchier RA, Sintnicolaas K, et al. (2002) The magnitude and specificity of influenza A virus-specific cytotoxic T-lymphocyte responses in humans is related to HLA-A and-B phenotype. J Virol 76: 582-590.
25. Jameson J, Cruz J, Ennis FA, (1998) Human cytotoxic T-lymphocyte repertoire to influenza A viruses. J Virol 72: 8682-8689.
26. Reiss CS, Schulman JL, (1980) Cellular immune responses of mice to influenza virus vaccines. J Immunol 125: 2182-2188.
27. Sha Z, Compans RW, (2000) Induction of CD4(+) T-cell-independent immunoglobulin responses by inactivated influenza virus. J Virol 74: 4999-5005.
28. Sawai T, Itoh Y, Ozaki H, Isoda N, Okamoto K, et al. (2008) Induction of cytotoxic T-lymphocyte and antibody responses against highly pathogenic avian influenza virus infection in mice by inoculation of apathogenic H5N1 influenza virus particles inactivated with formalin. Immunology 124: 155-165.
29. Cho Y, Basta S, Chen W, Bennink JR, Yewdell JW, (2003) Heat-aggregated noninfectious influenza virus induces a more balanced CD8(+)-T-lymphocyte immunodominance hierarchy than infectious virus. J Virol 77: 4679-4684.
30. Lee HK, Lund JM, Ramanathan B, Mizushima N, Iwasaki A, (2007) Autophagy-dependent viral recognition by plasmacytoid dendritic cells. Science 315: 1398-1401.
31. Hamada H, Garcia-Hernandez Mde L, Reome JB, Misra SK, Strutt TM, et al. (2009) Tc17, a unique subset of CD8 T cells that can protect against lethal influenza challenge. J Immunol 182: 3469-3481.
32. Huber M, Heink S, Grothe H, Guralnik A, Reinhard K, et al. (2009) A Th17-like developmental process leads to CD8(+) Tc17 cells with reduced cytotoxic activity. Eur J Immunol 39: 1716-1725.
33. Curtis MM, Way SS, Wilson CB, (2009) IL-23 promotes the production of IL-17 by antigen-specific CD8 T cells in the absence of IL-12 and type-I interferons. J Immunol 183: 381-387.
34. Hinrichs CS, Kaiser A, Paulos CM, Cassard L, Sanchez-Perez L, et al. (2009) Type 17 CD8+ T cells display enhanced antitumor immunity. Blood 114: 596-599.
35. Liu SJ, Tsai JP, Shen CR, Sher YP, Hsieh CL, et al. (2007) Induction of a distinct CD8 Tnc17 subset by transforming growth factor-beta and interleukin-6. J Leukoc Biol 82: 354-360.
36. Ciric B, El-behi M, Cabrera R, Zhang GX, Rostami A, (2009) IL-23 drives pathogenic IL-17-producing CD8+ T cells. J Immunol 182: 5296-5305.
37. Intlekofer AM, Banerjee A, Takemoto N, Gordon SM, Dejong CS, et al. (2008) Anomalous type 17 response to viral infection by CD8+ T cells lacking T-bet and eomesodermin. Science 321: 408-411.
38. Kondo T, Takata H, Matsuki F, Takiguchi M, (2009) Cutting edge: Phenotypic characterization and differentiation of human CD8+ T cells producing IL-17. J Immunol 182: 1794-1798.
39. Erard F, Wild MT, Garcia-Sanz JA, Le Gros G, (1993) Switch of CD8 T cells to noncytolytic CD8-CD4- cells that make TH2 cytokines and help B cells. Science 260: 1802-1805.
40. Croft M, Carter L, Swain SL, Dutton RW, (1994) Generation of polarized antigen-specific CD8 effector populations: reciprocal action of interleukin (IL)-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles. J Exp Med 180: 1715-1728.
41. Kienzle N, Buttigieg K, Groves P, Kawula T, Kelso A, (2002) A clonal culture system demonstrates that IL-4 induces a subpopulation of noncytolytic T cells with low CD8, perforin, and granzyme expression. J Immunol 168: 1672-1681.
42. Wrammert J, Koutsonanos D, Li GM, Edupuganti S, Sui J, et al. (2011) Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med 208: 181-193.
43. Epstein SL, (2006) Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature. J Infect Dis 193: 49-53.
44. Lee LY, Ha do LA, Simmons C, de Jong MD, Chau NV, et al. (2008) Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. J Clin Invest 118: 3478-3490.
45. Jameson J, Cruz J, Terajima M, Ennis FA, (1999) Human CD8+ and CD4+ T lymphocyte memory to influenza A viruses of swine and avian species. J Immunol 162: 7578-7583.
46. Kreijtz JH, de Mutsert G, van Baalen CA, Fouchier RA, Osterhaus AD, et al. (2008) Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte populations directed to human influenza A virus. J Virol 82: 5161-5166.
47. Kreijtz JH, Bodewes R, van Amerongen G, Kuiken T, Fouchier RA, et al. (2007) Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice. Vaccine 25: 612-620.
48. Tran TH, Nguyen TL, Nguyen TD, Luong TS, Pham PM, et al. (2004) Avian influenza A (H5N1) in 10 patients in Vietnam. N Engl J Med 350: 1179-1188.
49. Uiprasertkul M, Puthavathana P, Sangsiriwut K, Pooruk P, Srisook K, et al. (2005) Influenza A H5N1 replication sites in humans. Emerg Infect Dis 11: 1036-1041.
50. Jin Y, Zhang G, Hu Y, Ding M, Li Y, et al. (2011) Inhibition of highly pathogenic avian H5N1 influenza virus propagation by RNA oligonucleotides targeting the PB2 gene in combination with celecoxib. J Gene Med 13: 243-249.